Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis — AI Research | MarketCI

ALNY

Market Closed

Alnylam Pharmaceuticals, Inc.

NASDAQHealthcare Biotechnology

2.23K employees

CEO: Yvonne L. Greenstreet

Founded: 2004

$278.09

+$0.00(+NaN%)

Market Cap

37.13B

Beta

0.27

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

ALNY Price Chart

Historical price performance

Loading MCI price data...

MarketCI Investment Signals

AI-synthesized investment signal for ALNY built from valuation, fundamentals, sentiment, and risk models

Investment Signal

Hold

Pass %

57.14%

Score

4/7

Fair Value Estimate

Cash flow analysis • Multiple methods

-$1,811.65

AI Price Target

Machine learning • Price prediction

$275.34

Market Sentiment

News & social media analysis

0.04

Value Investor Price

Classic value analysis

$16.80

Financial Health

Bankruptcy risk assessment

5.71

Quality Score

Financial strength rating

6.00

AI Investment Grade

Deep analysis of filings & news

68.00

Key Investment Highlights

Important factors affecting ALNY investment thesis

Due Diligence Analysis

Investment criteria assessment and scoring

Overall Assessment

51.22% Good

Conditions Met

21.00/41.00

Due Diligence Score

51.22%

Due Diligence Conditions

Investment analysis conditions and results


	Pass
	Pass
	Pass
	Pass
	Pass
	Pass

Showing 1 to 6 of 46 conditions